Compare ClearPoint Neuro Inc (CLPT) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Okta, Inc. — how do they compare? ClearPoint Neuro Inc trades at $14.57 (market cap $454.21M), while Okta, Inc. trades at $151.36 (market cap $26.13B). The key difference: Okta, Inc. is far larger — about 57.5× ClearPoint Neuro Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | OKTA | |
|---|---|---|
Market Cap | $454.21M | $26.13B |
Sector | Health | Technology |
52-Week High | $29.60 | $154.62 |
52-Week Low | $8.66 | $62.93 |
Enterprise Value | $488.79M | $23.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
OKTA trades at $150.77, up 1.65% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $2.61B in 2025, achieving a net income of $28M after recent losses. The company maintains a 77.44% gross margin and positive operating cash flow of $750M, supported by strategic acquisitions like Permiso Security for AI threat defense.
Outlook remains positive with 72.55% analyst buy ratings and a consensus price target of $129.71, though high valuation ratios (P/E 108.93) and overbought RSI levels near 76.86 pose risks. Key catalysts include Q2 2026 earnings on August 26, 2026, and growth in cybersecurity demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
